CSPC Pharmaceutical Group Limited (CSPCY)
USD 3.05
(-2.71%)
USD 3.05
(-2.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.87 Billion CNY | -3.58% |
| 2022 | 6.09 Billion CNY | 8.67% |
| 2021 | 5.6 Billion CNY | 8.63% |
| 2020 | 5.15 Billion CNY | 38.92% |
| 2019 | 3.71 Billion CNY | 20.56% |
| 2018 | 3.08 Billion HKD | 33.08% |
| 2017 | 2.31 Billion HKD | 23.07% |
| 2016 | 1.88 Billion HKD | 34.9% |
| 2015 | 1.39 Billion HKD | 37.48% |
| 2014 | 1.01 Billion HKD | 33.44% |
| 2013 | 760.11 Million HKD | -56.34% |
| 2012 | 1.74 Billion HKD | 822.62% |
| 2011 | 188.7 Million HKD | -70.54% |
| 2010 | 640.6 Million HKD | -25.05% |
| 2009 | 854.68 Million HKD | 3.2% |
| 2008 | 828.16 Million HKD | 85.18% |
| 2007 | 447.21 Million HKD | 2803.15% |
| 2006 | 15.4 Million HKD | -90.53% |
| 2005 | 162.69 Million HKD | -37.77% |
| 2004 | 261.44 Million HKD | -51.23% |
| 2003 | 536.07 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.61 Billion CNY | 16.98% |
| 2024 Q2 | 1.4 Billion CNY | 0.0% |
| 2023 Q4 | 1.37 Billion CNY | -9.75% |
| 2023 Q2 | 1.53 Billion CNY | 7.65% |
| 2023 Q1 | 1.42 Billion CNY | -11.99% |
| 2023 FY | 5.87 Billion CNY | -3.58% |
| 2023 Q3 | 1.52 Billion CNY | -0.68% |
| 2022 Q3 | 1.5 Billion CNY | -3.85% |
| 2022 FY | 6.09 Billion CNY | 8.67% |
| 2022 Q1 | 1.4 Billion CNY | -9.85% |
| 2022 Q2 | 1.56 Billion CNY | 11.19% |
| 2022 Q4 | 1.62 Billion CNY | 8.12% |
| 2021 Q4 | 1.55 Billion CNY | 1.4% |
| 2021 FY | 5.6 Billion CNY | 8.63% |
| 2021 Q3 | 1.53 Billion CNY | -19.69% |
| 2021 Q1 | 1.74 Billion CNY | -10.45% |
| 2021 Q2 | 1.91 Billion CNY | 9.58% |
| 2020 Q1 | 1.26 Billion CNY | 25.6% |
| 2020 Q4 | 1.94 Billion CNY | 41.86% |
| 2020 FY | 5.15 Billion CNY | 38.92% |
| 2020 Q3 | 1.37 Billion CNY | 8.51% |
| 2020 Q2 | 1.26 Billion CNY | -0.21% |
| 2019 Q1 | 1.11 Billion CNY | 20.23% |
| 2019 Q3 | 1.02 Billion CNY | -2.92% |
| 2019 Q4 | 1.01 Billion CNY | -1.23% |
| 2019 FY | 3.71 Billion CNY | 20.56% |
| 2019 Q2 | 1.05 Billion CNY | -5.33% |
| 2018 Q1 | 924.4 Million CNY | 27.18% |
| 2018 Q2 | 907.76 Million CNY | -1.8% |
| 2018 Q3 | 869.26 Million CNY | -4.24% |
| 2018 Q4 | 925.93 Million CNY | 6.52% |
| 2018 FY | 3.08 Billion HKD | 33.08% |
| 2017 FY | 2.31 Billion HKD | 23.07% |
| 2017 Q4 | 726.82 Million CNY | -0.54% |
| 2017 Q3 | 730.77 Million CNY | 8.25% |
| 2017 Q2 | 675.04 Million CNY | 5.83% |
| 2017 Q1 | 637.88 Million CNY | 19.66% |
| 2016 Q3 | 534.94 Million CNY | 1.47% |
| 2016 Q4 | 533.09 Million CNY | -0.35% |
| 2016 Q2 | 527.19 Million CNY | 4.27% |
| 2016 FY | 1.88 Billion HKD | 34.9% |
| 2016 Q1 | 505.62 Million CNY | 19.77% |
| 2015 Q4 | 422.17 Million CNY | 0.26% |
| 2015 FY | 1.39 Billion HKD | 37.48% |
| 2015 Q3 | 421.07 Million CNY | -0.14% |
| 2015 Q2 | 421.68 Million CNY | 5.34% |
| 2015 Q1 | 400.32 Million CNY | 15.01% |
| 2014 Q4 | 348.07 Million CNY | 8.87% |
| 2014 FY | 1.01 Billion HKD | 33.44% |
| 2014 Q1 | 261.08 Million CNY | 22.22% |
| 2014 Q2 | 339.57 Million CNY | 30.06% |
| 2014 Q3 | 319.7 Million CNY | -5.85% |
| 2013 Q4 | 213.62 Million CNY | -12.43% |
| 2013 FY | 760.11 Million HKD | -56.34% |
| 2013 Q3 | 243.93 Million CNY | -17.71% |
| 2013 Q2 | 296.43 Million CNY | 35.51% |
| 2013 Q1 | 218.76 Million CNY | 0.0% |
| 2012 FY | 1.74 Billion HKD | 822.62% |
| 2011 FY | 188.7 Million HKD | -70.54% |
| 2010 FY | 640.6 Million HKD | -25.05% |
| 2009 FY | 854.68 Million HKD | 3.2% |
| 2008 FY | 828.16 Million HKD | 85.18% |
| 2007 FY | 447.21 Million HKD | 2803.15% |
| 2006 FY | 15.4 Million HKD | -90.53% |
| 2005 FY | 162.69 Million HKD | -37.77% |
| 2004 FY | 261.44 Million HKD | -51.23% |
| 2003 FY | 536.07 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 1.372% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 26.812% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -606.849% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 10493.058% |
| Novartis AG | 14.85 Billion USD | 60.449% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -3168.305% |